Green Fresh Biotechnology Company Limited Issues Significant Profit Warning for FY2025

Green Fresh Biotechnology Company Limited (Stock Code: 1084) has issued a profit warning for the financial year ended 31 December 2025, which could have a material impact on its share price and is critical information for current and prospective investors.

Key Highlights from the Profit Warning

• Substantial Decline in Net Profit: The Company expects to record a net profit attributable to owners of not more than RMB8.0 million for FY2025. This represents a dramatic decrease from the net profit of approximately RMB62.2 million recorded in FY2024.
• Primary Causes: The sharp deterioration in profitability is attributed to a significant drop in both the price and sales volume of the Group’s core hydrocolloid products. This has led to a decline in both revenue and gross profit for FY2025.
• Preliminary Figures: The profit figures disclosed are based on unaudited consolidated management accounts and are subject to change after review by the Company’s auditors and audit committee.
• Final Results Timeline: The Company expects to release its audited consolidated final results for FY2025 by the end of March 2026, in full compliance with the relevant Hong Kong Listing Rules.

Important Considerations for Shareholders and Investors

• Price-Sensitive Information: The expected drastic reduction in net profit for FY2025 is material and price sensitive. This may have a significant negative impact on the Company’s share price once fully reflected in the market.
• Caution Advised: Shareholders and prospective investors are strongly advised to exercise caution when dealing in the Company’s shares due to the potential for share price volatility until the final audited results are published.
• Ongoing Assessment: The disclosed financials are preliminary and subject to further adjustments. Investors should closely monitor subsequent announcements for any changes or additional material information.

Board and Management Update

The announcement was authorized by the Board of Directors, led by Chairman and Chief Executive Officer Mr. Chan Kam Chung. The Board comprises both executive and independent non-executive directors, reaffirming the Company’s adherence to corporate governance requirements.

Conclusion

This profit warning signals a challenging period for Green Fresh Biotechnology, driven by market and operational headwinds affecting its principal product lines. Investors should remain vigilant and monitor forthcoming announcements, particularly the audited results expected by March 2026, to make informed decisions regarding their investments in the Company.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should exercise their own judgment and consult professional advisers before making any investment decisions based on this information. The figures mentioned are preliminary and may be subject to change upon final audit.

View GREEN FRESH BIO Historical chart here